Relationship between NF-KB, ER, PR, HER2/NEU, KI67, P53 expression in human breast cancer

Experimental Oncology

Volumn 34, Issue 4, 2012, Pages 358-363

  Shapochka, D O ^a   Zaletok, S P ^a   Gnidyuk, M I ^b  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b Ivano Frankivsk Regional Oncology Dispensary ^*  (Ukraine)

Author keywords

Breast cancer; Her2 neu; Ki 67; Molecular subtype; NF B; p53; Receptors of steroid hormones

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MOLECULAR MARKER; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR RELA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; FEMALE; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM GRADING; NEOPLASM STAGING; NF-KAPPA B; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872393558     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cancer in Ukraine, 2008-2009: bulletin of national cancer registry of Ukraine No 11. Kyiv, 2010. 111 p.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
3. Klijin JGM. Clinical parameters and symptoms for the progression to endocrine independence of breast cancer. In: Mechanisms of Progression to Hormone-independent Growth of Breast and Prostatic Cancer. Carnfoth: The Parthenon Publishing Group, 1991; 11-9.
4. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-16. (Pubitemid 16020062)
5. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-8. (Pubitemid 17005065)
6. Leonardo M, Pierce JW, Baltimore D. Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility. Science 1987; 236: 1537-77.
7. Meteoglu I, Erdoghu IH, Meydan N, et al. NF-kappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res 2008; 27: 53.
8. Gromkowski SH, Mama K, Yagi J, et al. Double-stranded RNA and bacterial lipopolysacharide enhance sensitivity to TNF-alpha-mediated cell death. Int Immunol 1990; 2: 903-8. (Pubitemid 20307075)
9. Robbins MA, Maksumova L, Pocock E, et al. Nuclear factor-kappaB translocation mediates double-stranded ribonucleic acid-induced NIT-1 beta-cell apoptosis and up-regulates caspase-12 and tumor necrosis factor receptor-associated ligand (TRAIL). Endocrinology 2003; 144: 4616-25. (Pubitemid 37204861)
10. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin I stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989; 86: 2336-40. (Pubitemid 19102503)
11. Hazan U, Thomas D, Alcami J, et al. Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus I enhancer-dependent transcription. Proc Natl Acad Sci USA 1990; 87: 7861-5.
12. Visvanathan KV, Goodbourn S. Double stranged RNA activates binding of NF-kappa B to an inducible element in the human beta-interferon promoter. The EMBO J 1989; 8: 1129-38.
13. Shurman L, Sen R, Bergman Y. Adenovirus E1A products activate the Ig k-chain enhaner in fibroblasts. A possible involvement of the NF-kB binding site. J Immunol 1989; 142: 3806-12. (Pubitemid 20007058)
14. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of NF-kappa B transcription factor and HIV-1. The EMBO J 1991; 10: 2247-58. (Pubitemid 21905698)
15. Stein B, Kramer M, Rahmsdorf HJ, et al. UV-induced transcription from human Immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells. J Virol 1989; 63: 4540-4. (Pubitemid 19257828)
16. Faure E, Rameil P, Lecine P. Secretion of extracellular factor(s) induced by X-irradiation activates the HIV type 1 long terminal repeat through its kappaB motif. AIDS Research and human retroviruses 1998; 14: 353-65. (Pubitemid 28110674)
17. Hohman HP, Kobleck R, Remy R, et al. Cyclic AMP-independent activation of transcription factor NF-kappa B in HL60 cells by tumor necrosis factors alpha and beta. Mol Cell Biol 1991; 11: 2315-8. (Pubitemid 21895607)
18. Zabel U, Schreck R, Baeuerle PA. DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-life recognition. J Biol Chem 1991; 266: 252-60. (Pubitemid 21906116)
19. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-kabbaB/Rel expression and the progression of breast cancer. J Clin Invest 1997; 100: 2952-60. (Pubitemid 28022831)
20. Nakshatri H, Bhat-Nakshatri P, Martin DA, et al. Constitutive activation of NF-kappa B during the progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3269-639.
21. Ahmed A. Prognostic and therapeutic role of nuclear factor-kappa B (NF-kappaB) in breast cancer. J Ayub Med College 2010; 22: 218-21.
22. Beauparlant P, Kwan I, Bitar R, et al. Disruption of I kappa B alpha by antisense RNA expression leads to malignant transformation. Oncogene 1994; 9: 3189-97.
23. Bottex-Gauthier C, Pollet S, Favier A, et al. The Rel/NF-kappa-B transcription factors: complex role in cell regulation. Patologie-Biologie 2002; 50: 204-11. (Pubitemid 34288739)
24. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-7. (Pubitemid 26398259)
25. Arceci RJ. Tumor cell survival and resistance to therapy. Curr Opin Hematol 1996; 3: 279-87. (Pubitemid 26256685)
26. Gonzales-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
27. Montagut C, Tusquets I, Ferrer B, et al. Activation of nuclear factor-kB is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006; 13: 606-16.
28. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999; 55: 48-63. (Pubitemid 29077854)
29. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31. (Pubitemid 27131374)
30. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor nerrosis factor-induced apoptosis via the Akt/NF-κB pathway. J Biol Chem 2000; 275: 8027-31. (Pubitemid 30159714)
31. Biswas DK, Shi Q, Baily S, et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. PNAS 2004; 101: 10137-42. (Pubitemid 38891208)
32. Gershtein ES, Scherbakov AM, Platova AM, et al. The expression and DNA-binding activity of NF-κ B nuclear transcription factor in the tumors of patients with breast cancer. Bull Exp Biol Med 2010; 7: 80-4.
33. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κ B. J Clin Invest 2001; 107: 241-6. (Pubitemid 32157954)
34. Dabbs DJ. Diagnostic immunohistochemistry: theranostic and genomic applications, 3rd ed. Philadelphia: Saunders (Elsevier Science), 2010. 941 p.
35. Schepotin I.B. Clinical and biological features of triple negative breast cancer. Klin Oncol 2012; 5 (1): 55-8.
36. Gazzeri S, Brambilla E, Caron de Fromentel C, et al. p53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 1994; 58: 24-32. (Pubitemid 24213965)
37. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia- inducible factor 1alpha. Genes Devel 2000; 14: 34-44. (Pubitemid 30051577)
38. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010; 12: 207.